The makers of anti-cancer drug Revlimid have been hit with a suit in a New Jersey court accusing them of launching a multifaceted scheme to stave off generic competition.

Celgene and Bristol-Myers Squibb initiated the plan and were later joined by Natco, which sought to make a generic version of the drug, and Teva, its marketing partner, according to the suit filed Thursday in U.S. District Court by Kenny Nachwalter of Miami.